DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vigamox (Moxifloxacin Hydrochloride) - Published Studies


Vigamox Related Published Studies

Well-designed clinical trials related to Vigamox (Moxifloxacin)

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. [2014]

Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials. [2014]

Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study. [2013]

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. [2012]

Neither moxifloxacin nor cefuroxime produces significant attenuation of inflammatory mediator release in patients exposed to cardiopulmonary bypass: a randomized controlled trial. [2011.10.03]

The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil. [2011.09]

Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application. [2011.06]

Comparative efficacy and safety of moxifloxacin and clindamycin in the treatment of odontogenic abscesses and inflammatory infiltrates: a phase II, double-blind, randomized trial. [2011.03]

Efficacy and safety of adjunctive local moxifloxacin delivery in the treatment of periodontitis. [2011.01]

Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. [2011]

Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients. [2010.12]

Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. [2010.11]

Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. [2010.11]

Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies. [2010.11]

Evaluation of the effects of AZD3480 on cardiac repolarization: a thorough QT/QTc study using moxifloxacin as a positive control. [2010.10]

Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients. [2010.09]

A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects. [2010.08.01]

Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials. [2010.07]

Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis. [2010.05]

Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study. [2010.05]

Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial. [2010.04.15]

Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment. [2010.02]

Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. [2010.01.28]

[Efficacy of second-line treatment based on moxifloxacin triple therapy for Helicobacter pylori infection] [2010.01.12]

Effects of prulifloxacin on cardiac repolarization in healthy subjects: a randomized, crossover, double-blind versus placebo, moxifloxacin-controlled study. [2010]

Preoperative topical moxifloxacin 0.5% and povidone-iodine 5.0% versus povidone-iodine 5.0% alone to reduce bacterial colonization in the conjunctival sac. [2009.12]

Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. [2009.11]

Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. [2009.11]

A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. [2009.10]

One-day application of topical moxifloxacin 0.5% to select for fluoroquinolone-resistant coagulase-negative Staphylococcus. [2009.10]

Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. [2009.10]

Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. [2009.09]

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. [2009.08.01]

Prospective randomized comparison of 1-day and 3-day application of topical 0.5% moxifloxacin in eliminating preoperative conjunctival bacteria. [2009.08]

Electrocardiographic QTc changes due to moxifloxacin infusion. [2009.06]

Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects. [2009.06]

Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested. [2009.05]

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. [2009.04.04]

Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). [2009.04]

Patients' perception of recovery after third molar surgery following postoperative treatment with moxifloxacin versus amoxicillin and clavulanic acid: a randomized, double-blind, controlled study. [2009.02]

Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: a pilot study. [2009.01]

Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. [2009]

Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection. [2008.12]

Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. [2008.11]

A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. [2008.11]

Moxifloxacin as an adjunctive antibiotic in the treatment of severe chronic periodontitis. [2008.10]

The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. [2008.10]

Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. [2008.09]

Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. [2008.09]

Penetration and accumulation of moxifloxacin in uterine tissue. [2008.08]

Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. [2008.05.15]

Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given in different concentrations in a wick before cataract surgery. [2008.05]

A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial. [2008.05]

Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. [2008.03]

Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. [2008.01]

Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery. [2008.01]

Ototoxicity of Topical Moxifloxacin in a Chinchilla Animal Model. [2007.12]

Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. [2007.09]

High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. [2007.06]

Treatment of ankylosing spondylitis with moxifloxacin. [2007.04]

The effect of moxifloxacin and gatifloxacin on long-term visual outcomes following photorefractive keratectomy. [2007.04]

High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. [2007]

Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. [2006.12]

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. [2006.08.01]

Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration. [2006.08]

Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. [2006.08]

Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients. [2006.04]

Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. [2006.02]

Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. [2006.01.01]

A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. [2005.11]

Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. [2005.11]

Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. [2005.11]

The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy. [2005.07]

A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. [2005.06]

Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. [2005.06]

Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. [2005.05.15]

Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. [2005.05]

Penetration of moxifloxacin into the human aqueous humour after oral administration. [2005.05]

Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. [2005.03]

Ocular penetration of moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery. [2005.01]

Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. [2005]

A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability. [2004.11]

Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. [2004.11]

Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis. [2004.09]

Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. [2004.03]

Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. [2004.03]

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. [2004.03]

Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. [2004.02]

Sinus tissue concentration of moxifloxacin after a single oral dose. [2004.02]

Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. [2004.01]

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. [2003.12.01]

Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. [2003.12]

Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. [2003.10]

[A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial] [2003.09]

Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. [2003.01]

Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. [2003.01]

Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). [2002.12]

Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. [2002.06]

A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. [2002.05]

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. [2002.03]

Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. [2002]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017